PURPOSE–BUILT. PRECISION REPAIR. PRESERVES OPTIONS.
Intact Vascular is advancing clinical science to improve the treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI) following standard and drug-coated balloon angioplasty.
Click on any of the TOBA trials to learn more.
This multi-center, global pivotal study evaluates the Tack Endovascular System® (4F, 1.5-4.5mm) in patients with critical limb ischemia (CLI) and dissections resulting from percutaneous transluminal angioplasty (PTA) using a standard balloon in the mid/distal popliteal, tibial and/peroneal arteries.
TOBA II is designed to investigate the safety and efficacy of the Tack Endovascular System® (6F, 3.5-6.0mm) in patients with post-PTA dissection following POBA or Lutonix® DCB angioplasty in the SFA and proximal popliteal arteries.
12m K-M Freedom from CD-TLR
12m K-M Primary Patency
Bail Out Stent Rate
TOBA III is a European multi-center post-CE Mark study that continues the evaluation of dissection repair with the Tack Endovascular System® (6F, 3.5-6.0mm) following DCB angioplasty with the IN.PACT™ Admiral™ in the SFA and proximal popliteal arteries.
Lutonix® is a registered trademark of BD Interventional.
IN.PACT™ and Admiral™ are trademarks of Medtronic, Inc.